NCT04459078 2022-12-02
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
Hunan Cancer Hospital
Phase 2 Unknown
Clinical Trials
3 trialsNCT02691871 2016-02-25
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Unknown
NCT02493582 2016-02-05
The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
The First People's Hospital of Changzhou
Phase 2 Active not recruiting